Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.
Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback